Tübingen, Germany-based CureVac and Novartis have signed an initial manufacturing agreement that’s expected to boost the mRNA biotech’s overall vaccine capacity by 50 million doses in 2021 and 200 million doses in 2022. The partners are prepping for technology transfers and test runs, and deliveries from Novartis’ site in Kundl, Austria, are expected to start this summer. Under the deal, Novartis is expected to produce mRNA and bulk drug product for the vaccine. Source: Fierce Pharma 4/3/21